Arcutis Biotherapeutics (ARQT) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precigen (PGEN) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 136.0% versus a gain of 17.5%. Over five years, PGEN leads with a +63.4% price change compared with +8.5% for ARQT. Arcutis Biotherapeutics is the larger company by market cap ($3.08 billion vs $2.72 billion), about 1.1 times the size, while Precigen is growing revenue faster (+146.7% vs +91.3%).
Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | PGEN |
|---|---|---|
| Share price | $24.49 | $7.60 |
| Market cap | $3.08B | $2.72B |
| 1-day change | +1.32% | +0.80% |
| YTD return | -16.77% | +81.82% |
| 1-year return | +17.50% | +136.02% |
| 5-year return | +8.48% | +63.44% |
| P/E ratio (TTM) | 111.32 | — |
| Forward P/E | 18.01 | — |
| EPS (TTM) | $0.22 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $9.68M |
| Revenue growth (YoY) | +91.34% | +146.73% |
| Net income (latest FY) | $-16.14M | $-250.64M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | -1141.13% |
| Net margin | -4.29% | -2588.21% |
| 52-week high | $31.77 | $8.98 |
| 52-week low | $19.30 | $2.99 |
| Distance from 52-week high | -22.91% | -15.37% |
| Analyst consensus | none | buy |
| Avg. price target upside | +51.08% | +79.61% |
| Average volume | 2.22M | 5.02M |
| Shares outstanding | 125.69M | 358.04M |
| Employees | 354 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed ARQT by 118.5 percentage points over the past year.
- Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs +91.34%).
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
ARQT vs PGEN FAQ
Which is bigger, Arcutis Biotherapeutics or Precigen?
Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.08B compared with $2.72B for Precigen (PGEN).
Which stock has performed better over the past year, ARQT or PGEN?
PGEN returned +136.02% over the past 12 months, compared with +17.50% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.